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In a population-based cohort study of all women aged over 50 years with breast cancer in the Swedish Cancer Register in 1961–
2003, those diagnosed before 31 December 1987 were regarded as unexposed to tamoxifen, whereas those diagnosed after that
date were considered potentially exposed. Crosslinkages within the Cancer Register and the Registers of Death and Emigration
enabled follow-up. Standardised incidence ratios (SIRs) of oesophageal and gastric cancer represented relative risks. Among 138885
cohort members contributing with 1075724 person-years of follow-up, we found a nonsignificantly increased risk of oesophageal
adenocarcinoma during the potential tamoxifen exposure period (SIR 1.60, 95% confidence interval (CI) 0.83–3.08), but the risk
estimates decreased with increasing latency interval. No association was observed during the unexposed period. No increased risk of
cardia adenocarcinoma was identified in either period. The risk of non-cardia gastric adenocarcinoma was increased in the potential
tamoxifen period (SIR 1.27, 1.03–1.57), and almost doubled (SIR 1.86, 95% CI 1.10–3.14) in the period of longest latency (10–14
years). The corresponding overall SIR was increased in the unexposed group also, but here SIR did not increase with longer latency
intervals. An increased risk of tobacco-related tumours, that is, oesophageal squamous-cell carcinoma and lung cancer, was limited to
the unexposed cohort, indicating that confounding by smoking might explain the increased SIR during the unexposed period. We
concluded that there might be a link between tamoxifen and risk of non-cardia gastric adenocarcinoma.
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The male predominance is a striking but as yet unexplained
characteristic shared by patients diagnosed with oesophageal and
gastric adenocarcinoma. The male to female ratio for oesophageal
and cardia adenocarcinoma is about 6–7 to 1, whereas this ratio is
about 2–3 to 1 for non-cardia gastric adenocarcinoma (Fuchs and
Mayer, 1995; Parkin, 2001). As this pattern is not explained by sex
differences in the exposure to known risk factors, sex hormonal
influence has been hypothesised (Lagergren and Nyren, 1998;
Sipponen and Correa, 2002), but requires further investigation.
Whereas the limited available literature does not support a role
of oestrogen in the aetiology of oesophageal adenocarcinoma
(Lagergren and Nyren, 1998; Lagergren and Jansson, 2005;
Lindblad et al, 2006a), data are accumulating in favour of
oestrogen influence on the aetiology of gastric adenocarcinoma,
a decreased risk of which has been reported among women treated
with postmenopausal hormone replacement therapy (HRT)
(Lindblad et al, 2006a) and among men with prostate cancer
treated with oestrogen (Lindblad et al, 2004), suggesting that
oestrogen has a protective effect.
Tamoxifen is a selective oestrogen receptor modulator with
antioestrogenic effects in the breast and oestrogenic activity in
various tissues such as the endometrium and bone. It has been
widely used in the treatment of oestrogen-dependent breast cancer
since the drug was introduced about 30 years ago, and its use in
Sweden has been widespread since the late 1980s (Fornander et al,
1989). To explore the potential role of sex hormonal influence in
the aetiology of oesophageal and gastric adenocarcinoma, we
investigated whether tamoxifen-treated postmenopausal women
with breast cancer were at increased risk of developing oesopha-
geal or gastric adenocarcinoma in a nationwide Swedish popula-
tion-based cohort study.
MATERIALS AND METHODS
Study cohort
The Swedish Cancer Register was established in 1958 in order to
build a complete cancer database for clinical and epidemiological
research purposes. All clinicians and pathologists in Sweden are
obliged to report all cancer cases to the Registry. Validation studies
have shown that the register has a completeness rate of 98%
(Lindblad et al, 2006b) and virtually all cancer cases (99%) are
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ymorphologically verified (Socialstyrelsen, 2005). In addition to the
cancer diagnosis, the Cancer Register contains data on sex, date of
birth, date of diagnosis, codes for specific sites and histology of
cancers, and hospital codes. The Register was used to identify a
study cohort of all postmenopausal women (age X50 years) in
Sweden with a first primary breast cancer during the period 1
January 1961 to 31 December 2003. For possible confounding by
smoking, we also analysed the risk of tobacco-related cancers, that
is, oesophageal squamous-cell carcinoma and lung cancer. Only
patients with a first and primary breast cancer were included, that
is, patients with a previous cancer were excluded, as were patients
with a secondary breast cancer. The patients were identified by a
unique 10-digit personal registration number given to each
Swedish resident at birth or at immigration. This identifier made
register linkages possible.
Follow-up
Crosslinkage within the Cancer Register identified all patients in
our cohort who at any time after the first diagnosis of breast cancer
developed an oesophageal or gastric adenocarcinoma, with the
following ICD codes for the period 1961–1968: oesophageal cancer
150, gastric cancer 151; 1969–1986: oesophageal cancer 150,
gastric cancer 151.0/1/8/9; 1987–1996: oesophageal cancer 150.0-5/
8/9, gastric cancer 151.0-9 except for 151.7; 1997–2003: oesopha-
geal cancer C15.0-5/8/9, gastric cancer C16.0-9 except for C16.7.
The histology code for adenocarcinoma was 096 and for
squamous-cell carcinoma 146, and these codes were used during
the entire study period. As the Cancer Register has been
nationwide since 1961, this was used as the start of the follow-up
period for our cohort. This register has distinguished between
cardia and non-cardia gastric cancer since 1970. Linkage to the
Registers of Causes of Death and Emigration identified deaths and
emigrations among the cohort members during the study period.
Statistical analysis
Relative risks were estimated by calculating the standardised
incidence ratio (SIR), that is, the ratio of observed to expected
number of newly diagnosed oesophageal and gastric cancer cases.
The expected number of cases was calculated by multiplying the
observed number of person-years by age-specific and calendar
year-specific incidence rates, in 5-year interval, derived from the
entire Swedish female population. When calculating the 95%
confidence interval (CI) of SIR, we assumed that the number of
cases followed a Poisson distribution. All oesophageal and gastric
cancer diagnoses occurring within 1 year of follow-up after the
primary breast cancer diagnosis were excluded to minimise
surveillance bias, that is, a patient with a newly diagnosed breast
cancer would be more likely to have another cancer diagnosis
detected because of the ongoing diagnostic investigations for the
breast cancer. As widespread use of tamoxifen in Sweden only
began in the late 1980s (Fornander et al, 1989), we considered the
cohort of women diagnosed with breast cancer up to the end of
December 1987 as being unexposed to tamoxifen, whereas the
cohort diagnosed after that date was considered potentially
exposed. Women younger than 50 years of age at the time of the
breast cancer diagnosis were considered premenopausal and were
excluded from the analysis.
Ethics
The regional ethics committee at Karolinska Institutet in Stock-
holm, Sweden, approved this study.
RESULTS
Oesophageal adenocarcinoma
Among 138885 postmenopausal women with breast cancer in our
total study cohort, contributing with a total of 1075724 person-
years of follow-up (mean follow-up 7.74 years), we identified 19
patients with oesophageal adenocarcinoma (SIR 1.34, 95% CI
0.85–2.11) (Table 1). In the potentially exposed cohort, nine
patients with oesophageal adenocarcinoma were identified, which
meant a 60% statistically nonsignificant increase in the risk of
developing this tumour (SIR 1.60, 95% CI 0.83–3.08), but the risk
Table 1 Characteristics of a cohort of postmenopausal Swedish women with a breast cancer diagnosis between 1961 and 2003, and SIR, with 95% CI, of
oesophageal adenocarcinoma
Oesophageal adenocarcinoma
Unexposed (1961–1987) Exposed (1988–2003) Total cohort (1961–2003)
No. of breast cancer cases 73377 65508 138885
No. of person-years at risk 711837 363887 1075724
Mean years of follow-up 9.70 5.55 7.74
Mean age at entry (range) 68 (50–101) 68 (50–104) 68 (50–104)
No. of observed oesophageal adeno-carcinoma cases 10 9 19
No. of expected oesophageal adeno-carcinoma cases 8.49 5.61 14.10
SIR (95% CI) 1.17 (0.63–2.18) 1.60 (0.83–3.08) 1.34 (0.85–2.11)
Latency interval after breast cancer diagnosis in years Number of observed cases of oesophageal adenocarcinoma
SIR (95% CI)
1–4 1 5 6
0.61 (0.08–4.36) 1.85 (0.77–4.44) 1.38 (0.62–3.08)
5–9 3 3 6
1.68 (0.54–5.22) 1.44 (0.46–4.47) 1.55 (0.69–3.46)
10–14 3 1 4
1.67 (0.54–5.20) 1.23 (0.17–8.74) 1.53 (0.57–4.10)
415 3 0 3
0.90 (0.29–2.81) 0.90 (0.29–2.80)
CI¼confidence interval; SIR¼standardised incidence ratio. Patients diagnosed with breast cancer between 1961 and 1987 were considered unexposed to tamoxifen treatment,
whereas those diagnosed between 1988 and 2003 were considered exposed. First year of follow-up was excluded.
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cancer diagnosis. In the unexposed cohort, the risk of oesophageal
adenocarcinoma was not increased (1.17, 95% CI 0.63–2.18), and
no trend associated with an increasing latency interval was found
(Table 1).
Gastric cardia adenocarcinoma
Among 119148 breast cancer patients, contributing 892555
person-years of follow-up, for whom data on the cardia site were
available (from 1970), we identified 21 cases of gastric cardia
adenocarcinoma (Table 2). The risk of cardia adenocarcinoma was
not increased either in the potentially tamoxifen-exposed cohort
(0.96, 95% CI 0.5–1.86) or in the unexposed cohort (SIR 0.75, 95%
CI 0.42–1.32), and there was no increase in the risk of cardia
adenocarcinoma with increasing latency interval after breast
cancer diagnosis (Table 2). The analysis of all gastric cardia
cancers (n¼24), that is, without specification of histologic type,
yielded results similar to the analysis of the specified adenocarci-
noma cases (data not shown).
Gastric non-cardia adenocarcinoma
During follow-up of the cohort of 119148 patients with 892555
person-years (from 1970), 341 cases of gastric non-cardia
adenocarcinoma were identified, which meant an overall increase
in the risk of this cancer (SIR 1.41, 95% CI 1.27–1.57) (Table 3). In
the potentially tamoxifen-exposed group, there was a 27%
statistically significant increase in the risk of gastric non-cardia
adenocarcinoma (SIR 1.27, 95% CI 1.03–1.57), and the risk
estimates increased with increasing latency time after breast cancer
diagnosis. In the longest studied time interval of follow-up in this
cohort (10–14 years), the point estimate was increased nearly two-
fold (SIR 1.86, 95% CI 1.10–3.14). In the unexposed cohort, an
overall 47% statistically significantly increase in the risk was found
(SIR 1.47, 95% CI 1.30–1.66), but with increasing latency interval
after breast cancer diagnosis, the risk estimates rather decreased
(Table 3). In the analyses of all gastric cancers, including tumours
without specification of histologic type or gastric subsite (n¼598),
gastric adenocarcinoma without site-specific information
(n¼503), and gastric non-cardia cancer without histologic
specification (n¼405), the risk estimates were all generally similar
to those presented for tumours specified as gastric non-cardia
adenocarcinomas (data not shown).
Oesophageal squamous-cell carcinoma and lung cancer
In the cohort unexposed to tamoxifen, there was an overall
increase in the risk of oesophageal squamous-cell carcinoma (SIR
1.56, 95% CI 1.21–2.02) and also seemingly in the risk of lung
cancer (1.10, 95% CI 0.99–1.22). In the potentially exposed cohort,
no such increase in the risk of either oesophageal squamous-cell
carcinoma (0.99, 95% CI 0.59–1.64) or lung cancer (0.84, 95% CI
0.73–0.97) was found.
DISCUSSION
In this study, we found no significant increase in the risk of
oesophageal adenocarcinoma among women with breast cancer,
and no link between breast cancer and gastric cardia adenocarci-
noma. An overall increase in the risk of gastric non-cardia
adenocarcinoma was found, and although the risk estimate of
gastric non-cardia adenocarcinoma was higher in women not
exposed to tamoxifen than in potentially tamoxifen-treated
women, an influence of tamoxifen may conceivably still exist.
The increased risk of both oesophageal squamous-cell carcinoma
and lung cancer during the unexposed period indicates an
increased level of smoking among women with breast cancer
during this period. No such increases were found during the
potential exposure to tamoxifen period. As smoking is linked with
a two- to three-fold increase in the risk of gastric non-cardia
adenocarcinoma (Lindblad et al, 2005), the increased risk in the
unexposed cohort might be explained by confounding by smoking,
whereas no such confounding could explain the statistically
significant increase in risk in the potentially tamoxifen-exposed
cohort. Moreover, as a longer latency period between breast cancer
and gastric cancer could represent a longer duration of tamoxifen
Table 2 Characteristics of a cohort of postmenopausal Swedish women with a breast cancer diagnosis between 1970 and 2003, and SIR, with 95% CI, of
gastric cardia adenocarcinoma
Gastric cardia adenocarcinoma
Unexposed (1970–1987) Exposed (1988–2003) Total cohort (1970–2003)
No. of breast cancer cases 53643 65505 119148
No. of person-years at risk 528789 363765 892555
Mean years of follow-up 9.85 5.55 7.49
Mean age at entry (range) 69 (50–101) 68 (50–104) 68 (50–104)
No. of observed gastric cardia adenocarcinoma cases 12 9 21
No. of expected gastric cardia adeno-carcinoma cases 15.95 9.28 25.24
SIR (95% CI) 0.75 (0.42–1.32) 0.96 (0.5–1.86) 0.83 (0.54–1.27)
Latency interval after breast cancer diagnosis in years Number of observed cases of gastric cardia adenocarcinoma
SIR (95% CI)
1–4 3 5 8
0.73 (0.23–2.28) 1.03 (0.43–2.48) 0.89 (0.44–1.79)
5–9 3 3 6
0.68 (0.21–2.11) 0.93 (0.30–2.89) 0.78 (0.35–1.75)
10–14 3 1 4
0.85 (0.27–2.65) 0.82 (0.11–5.86) 0.84 (0.31–2.26)
415 3 0 3
0.75 (0.24–2.33) 0.74 (0.24–2.32)
CI¼confidence interval; SIR¼standardised incidence ratio. Patients diagnosed with breast cancer between 1970 and 1987 were considered unexposed to tamoxifen treatment,
whereas those diagnosed between 1988 and 2003 were considered exposed. First year of follow-up was excluded. The earliest data available for the gastric cancer diagnosis
were from 1961, but distinction between cardia and non-cardia diagnoses was only available from 1970.
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increasing latency time, limited to the potentially exposed period,
further argues in favour of a tamoxifen-mediated mechanism.
This is the largest study to investigate oesophageal or gastric
adenocarcinoma risk after breast cancer. We used a population-
based cohort design and included virtually all postmenopausal
female breast cancer patients throughout Sweden diagnosed
during a period of more than 40 years. This should have reduced
the risk of selection bias and chance errors. Furthermore, the
Cancer Register data are of high validity (Lindblad et al, 2006b).
Another strength of the study is the virtually complete follow-up of
all cohort members, which was made possible through cross-
linkage of complete population registers, and the personal
identification numbers that are allocated to each Swedish resident.
Moreover, the homogeneous health-care system in Sweden
eliminates the risk of misreporting different regions of the
country. An important limitation is our lack of information about
the tamoxifen treatment in the individual patients, which
introduces exposure misclassification. Given that it was not until
the late 1980s that tamoxifen treatment started to be used widely in
Sweden (Fornander et al, 1989), we decided to regard all
postmenopausal women with breast cancer before 1988 as not
treated with tamoxifen and patients diagnosed later as potentially
so treated. Exposure misclassification should however be non-
differential and thus dilute any true associations and would
therefore not explain the positive associations found in our study.
Furthermore, confounding might have influenced our result.
The increased SIR for gastric cancer in our breast cancer cohort
indicates that this cohort is exposed to additional risk factors for
gastric cancer compared to the background female population.
Our analysis of SIR inherently adjusts for confounding by age and
calendar year, and as discussed above, we assessed influence of
tobacco smoking through analysis of tobacco-related cancer.
Confounding by smoking might be of particular relevance for
the interpretation of our results. Knowledge of the hazard of
smoking may have had a larger impact on the smoking habits of
breast cancer patients compared to the background population
and more so during the years 1988–2003 than in the earlier period
when the risks related to smoking were less known. We could not
adjust for other possible confounding factors, that is, socio-
economic status, heredity, diet, body mass, reflux disease, and
infection with H. pylori, but potential confounding any of these
factors does not seem likely to explain the pattern of elevated risks
identified in this study. Gastrooesophageal reflux and infection
with Helicobacter pylori have not been associated with breast
cancer, thus eliminating these as confounders. Lastly, despite the
large number of person-years followed up in this study, the low
incidence of oesophageal and cardia adenocarcinoma among
women implied imprecise risk estimates, and although we did
not identify an association between tamoxifen and oesophageal
adenocarcinoma with statistical significance, the point estimates
showed that in view of the risk of a type II error, a true association
cannot be ruled out. The results regarding gastric cancer were,
however, more robust.
The few previous studies that have addressed sex hormonal
influence in the aetiology of oesophageal and cardia adenocarci-
noma do not support any such influence, which seems to be in line
with our results. No decreased risk of oesophageal adenocarcino-
ma was observed in a cohort of prostate cancer patients treated
with oestrogen (Lagergren and Nyren, 1998), or among post-
menopausal women treated with oestrogen (Lindblad et al, 2006a).
Breastfeeding has been associated with a reduced risk of
oesophageal adenocarcinoma (Cheng et al, 2000), a finding that
does suggest sex hormonal influence, but childbearing has not
been found to be linked with a risk of this cancer (Lagergren and
Jansson, 2005). Moreover, no association between tamoxifen and
risk of oesophageal cancer has been previously observed
(Andersson et al, 1991; Rutqvist et al, 1995; Curtis et al, 1996;
Matsuyama et al, 2000).
Our study indicates that women with breast cancer are at
increased risk of gastric adenocarcinoma, and antioestrogen
therapy might explain this finding. Recently, a unique global
pattern in the male to female ratio of the incidence of gastric
adenocarcinoma was reported, indicating a 10–15-year delay in
this cancer among female subjects compared to male subjects,
possibly owing to the oestrogen exposure (Sipponen and Correa,
Table 3 Characteristics of a cohort of postmenopausal Swedish women with a breast cancer diagnosis between 1970 and 2003, and SIR, with 95% CI, of
gastric non-cardia adenocarcinoma
Gastric non-cardia adenocarcinoma
Unexposed (1970–1987) Exposed (1988–2003) Total cohort (1970–2003)
No. of breast cancer cases 53643 65505 119148
No. of person-years at risk 528789 363765 892555
Mean years of follow-up 9.85 5.55 7.49
Mean age at entry (range) 69 (50–101) 68 (50–104) 68 (50–104)
No. of observed gastric non-cardia adenocarcinoma cases 257 84 341
No. of expected gastric non-cardia adeno-carcinoma cases 174.52 65.88 240.39
SIR (95% CI) 1.47 (1.30–1.66) 1.27 (1.03–1.57) 1.41 (1.27–1.57)
Latency interval after breast cancer diagnosis in years Number of observed cases of gastric non-cardia adenocarcinoma
SIR (95% CI)
1–4 105 46 151
1.7 (1.4–2.06) 1.29 (0.96–1.72) 1.55 (1.32–1.82)
5–9 71 24 95
1.4 (1.11–1.77) 1.06 (0.71–1.58) 1.3 (1.06–1.58)
10–14 39 14 53
1.19 (0.87–1.63) 1.86 (1.1–3.14) 1.32 (1.008–1.72)
415 42 0 42
1.41 (1.04–1.91) 1.4 (1.04–1.9)
CI¼confidence interval; SIR¼standardised incidence ratio. Patients diagnosed between 1970 and 1987 were considered unexposed to tamoxifen treatment, whereas those
diagnosed between 1988 and 2003 were considered exposed. First year of follow-up was excluded. The earliest data available for the gastric cancer diagnosis were from 1961,
but distinction between cardia and non-cardia diagnoses was only available from 1970.
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prostate cancer have a reduced risk of developing gastric
adenocarcinoma (Lindblad et al, 2004), and in postmenopausal
women on HRT, the risk of gastric non-cardia adenocarcinoma
seems to be more than 50% lower than in those not receiving such
therapy (Lindblad et al, 2006a). Some reproductive factors have
also been studied in relation to gastric cancer risk. Early menarche,
late menopause, and nulliparity seem to increase the risk of breast
cancer (Bernstein, 2002). A longer fertility period might reduce the
gastric cancer risk (La Vecchia et al, 1994; Palli et al, 1994; Kaneko
et al, 2003) and multiparity has been linked with a decreased risk
(Kaneko et al, 2003). These results have been contradicted,
however (Plesko et al, 1985; La Vecchia et al, 1994; Heuch and
Kvale, 2000; Inoue et al, 2002). There are some previous results
that suggest an increased risk of gastric adenocarcinoma among
tamoxifen-treated patients. A pooled analysis of three studies in
Scandinavia found a nonsignificantly, but nearly three-fold
increased risk of gastric cancer (Rutqvist et al, 1995), and
correspondingly elevated risks have been found also in other
studies (Andersson et al, 1991; Curtis et al, 1996; Matsuyama et al,
2000). Finally, a trend of decreased survival among patients with
gastric cancer who had been treated with tamoxifen and in whom
the gastric cancer was positive for oestrogen receptors was
observed in a randomised trial (Harrison et al, 1989). Although,
taken together, all these previous studies suggest that tamoxifen
might play a role in the aetiology of gastric adenocarcinoma, the
association has not been established. Our study adds further
support however for a harmful effect of antioestrogen therapy with
regard to the risk of developing gastric non-cardia adenocarcinoma.
In conclusion, this study indicates that women who have had a
breast cancer diagnosis are at an increased risk of later developing
non-cardia gastric adenocarcinoma, possibly as a result of
tamoxifen exposure. No such effect was clearly demonstrated for
oesophageal or cardia adenocarcinoma. This study should
encourage further studies of the influence of sex hormonal
influence in the aetiology of these tumours.
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